Universe Pharmaceuticals (NASDAQ:UPC) Shares Up 15.8% – What’s Next?

Universe Pharmaceuticals INC (NASDAQ:UPC)’s share price traded up 15.8% during trading on Thursday . The stock traded as high as $3.16 and last traded at $3.16. 9,287 shares changed hands during mid-day trading, an increase of 80% from the average session volume of 5,156 shares. The stock had previously closed at $2.73.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Universe Pharmaceuticals in a report on Tuesday, February 3rd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Universe Pharmaceuticals currently has a consensus rating of “Sell”.

Universe Pharmaceuticals Stock Performance

The business’s fifty day moving average price is $3.06 and its 200 day moving average price is $3.93.

Universe Pharmaceuticals (NASDAQ:UPC) last posted its quarterly earnings data on Thursday, January 29th. The company reported $0.69 earnings per share for the quarter. The company had revenue of $8.92 billion during the quarter.

Universe Pharmaceuticals Company Profile

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.